Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2005-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10549-004-7751-xPMID 15952058
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen

  2004cited by this paper
• Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6

  2004cited by this paper
• Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4.

  2004cited by this paper
• Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

  2003cited by this paper
• Meta-analysis of vascular and neoplastic events associated with tamoxifen

  2003cited by this paper
• Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases.

  2002cited by this paper
• Effect of 4-hydroxytamoxifen isomers on growth and ultrastructural aspects of normal human breast epithelial (HBE) cells in culture.

  2002cited by this paper
• Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy.

  2002influential reference
• Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.

  2002cited by this paper
• Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer.

  2001cited by this paper
• Relationship of phenol sulfotransferase activity (SULT1A1) genotype to sulfotransferase phenotype in platelet cytosol.

  2000cited by this paper
• Expression of the androgen metabolizing enzyme UGT2B15 in adipose tissue and relative expression measurement using a competitive RT–PCR method

  1999cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• High frequency of CYP2D6 poor and "intermediate" metabolizers in black populations: a review and preliminary data.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

  1997cited by this paper
• Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype.

  1997cited by this paper
• Overlapping PCR for bidirectional PCR amplification of specific alleles: a rapid one-tube method for simultaneously differentiating homozygotes and heterozygotes.

  1997cited by this paper
• Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene.

  1997cited by this paper
• Recent trends in U.S. breast cancer incidence, survival, and mortality rates.

  1996cited by this paper
• Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates.

  1994cited by this paper
• Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study.

  1994cited by this paper
• Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.

  1992cited by this paper
• The UDP Glucuronosyltransferase Gene Super family: Suggested Nomenclature Based on Evolutionary Divergence

  1991cited by this paper
• Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro.

  1990cited by this paper
• Tamoxifen use, oestrogen binding and serum lipids in postmenopausal women with breast cancer.

  1990cited by this paper
• Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.

  1989cited by this paper
• Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile.

  1988cited by this paper
• Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro.

  1988cited by this paper
• Tamoxifen, serum lipoproteins and cardiovascular risk.

  1988cited by this paper
• Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterizing the activity of individual isomers.

  1985cited by this paper
• The pharmacology and clinical uses of tamoxifen.

  1984cited by this paper
• Geometric isomers of substituted triphenylethylenes and antiestrogen action.

  1981cited by this paper

• Impact of Complex Genetic and Drug–Drug Interactions on Tamoxifen Metabolism and Efficacy

  2025cites this paper
• CYP2D6 polymorphisms and endoxifen concentration in Chinese patients with breast cancer

  2025cites this paper
• Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data

  2024influential citation
• CYP2D6 Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis.

  2024cites this paper
• Drug Repurposing and Molecular Insights in the Fight Against Breast Cancer

  2024cites this paper
• Role of Personalized Medicine in Clinical Practice: An Overview of Current and Future Perspectives

  2024cites this paper
• Genotypic variations of the CYP2D6 gene in patients with breast cancer treated with tamoxifen: case series

  2023cites this paper
• Hormonothérapie des cancers du sein en situations adjuvante, métastatique et néoadjuvante

  2022cites this paper
• Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer

  2022cites this paper
• Ratios of Acetaminophen Metabolites Identify New Loci of Pharmacogenetic Relevance in a Genome-Wide Association Study

  2022cites this paper
• Drug Repurposing in Cancer Therapy: Influence of Patient’s Genetic Background in Breast Cancer Treatment

  2022cites this paper
• Pharmacogenetics of Drugs Used in the Treatment of Cancers

  2022cites this paper
• Ovalbumin and Poly(i:c) Encapsulated Dendritic Cell‐Targeted Nanoparticles for Immune Activation in the Small Intestinal Lymphatic System

  2022cites this paper
• Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis

  2022cites this paper
• Pharmacogenetic testing-guided treatment for oncology: an overview of reviews.

  2022cites this paper
• Factors Influencing Pharmacokinetics of Tamoxifen in Breast Cancer Patients: A Systematic Review of Population Pharmacokinetic Models

  2022cites this paper
• Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients

  2021cites this paper
• Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives.

  2021cites this paper
• SULT genetic polymorphisms: physiological, pharmacological and clinical implications

  2021cites this paper
• Endoxifen, an Estrogen Receptor Targeted Therapy: from Bench to Bedside.

  2021cites this paper
• Pharmacogenomics and Personalized Medicine

  2020cites this paper
• Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer

  2020cites this paper
• Recent advances in the personalized treatment of estrogen receptor-positive breast cancer with tamoxifen: a focus on pharmacogenomics

  2020cites this paper
• Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients

  2019cites this paper
• Breast cancer susceptibility genes in estrogen metabolizing pathway in a southern Indian population

  2019cites this paper
• The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China

  2019cites this paper
• Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites

  2019cites this paper
• The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms.

  2019cites this paper
• Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen

  2019cites this paper
• Safety and Effective Biomakers in Oncology

  2019cites this paper
• A genome-wide association study identifies three novel genetic markers for response to tamoxifen: A prospective multicenter study

  2018cites this paper
• The Underrated Risks of Tamoxifen Drug Interactions

  2018cites this paper
• The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population

  2018influential citation
• Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer

  2018cites this paper
• Review: Using physiologically based models to predict population responses to phytochemicals by wild vertebrate herbivores.

  2018cites this paper
• Pharmacogenomics and Pharmacoepigenomics: Impact on Therapeutic Strategies

  2018cites this paper
• Host-dependent variables: The missing link to personalized medicine.

  2018cites this paper
• CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study

  2018cites this paper
• Endocrine Therapy for Breast Cancer

  2018cites this paper
• Multi-ethnic SULT1A1 copy number profiling with multiplex ligation-dependent probe amplification.

  2018cites this paper
• Estrogènes : physiologie et aspects moléculaires

  2018cites this paper
• Clinical Pharmacogenomics Of Human Cyp2d6

  2018cites this paper
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

  2018cites this paper
• A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third‐Generation Aromatase Inhibitors

  2017cites this paper
• The outcomes of tamoxifen therapy in breast cancer patients and genotypes of SULT1A1 and glucuronosyltransferase

  2017influential citation
• From Genotype to Phenotype: Cytochrome P450 2D6-Mediated Drug Clearance in Humans.

  2017cites this paper
• Does CYP2D6 Genotyping have a Role in Guiding Tamoxifen Therapy

  2017cites this paper
• Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes

  2017cites this paper
• CYP 2 D 6 Testing in Breast Cancer : Ready for Prime Time ?

  2017cites this paper
• The Role of Genetic Testing in the Selection of Therapy for Breast Cancer: A Review

  2017cites this paper
• CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study

  2017cites this paper
• Impact of ABCB 1 and CYP 2 D 6 polymorphisms on tamoxifen treatment outcomes and adverse events in breast cancer patients

  2017cites this paper
• Cytochrome P450 Bioconjugate as a Nanovehicle for Improved Chemotherapy Treatment.

  2017cites this paper
• Impact of ABCB1 and CYP2D6 polymorphisms on tamoxifen treatment outcomes and adverse events in breast cancer patients.

  2017cites this paper
• Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen

  2017influential citation
• Genetic Testing for Tamoxifen Treatment Policy

  2017cites this paper
• Statistical assessment of repeated measures data with application in oncology

  2017cites this paper
• Pharmacogenomics of Tamoxifen

  2016cites this paper
• Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors.

  2016cites this paper
• Incidence of inactive allele CYP2D6*4 among Greek women suffering from hormone-sensitive breast cancer.

  2016cites this paper
• Investigation of the pharmacogenetics of colorectal cancer

  2016cites this paper
• Tamoxifen, CYP2D6 and endoxifen in the treatment of hormone sensitive breast cancer: demystifying the connections

  2016cites this paper
• Pharmacogenomics of Breast Cancer

  2016cites this paper
• Tamoxifen and Antidepressant Drug Interaction Among a Cohort of 16 887 Breast Cancer Survivors

  2016cites this paper
• Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study

  2016cites this paper
• PREVALENCE OF CYP2D6*4 GENOTYPE AND ITS ASSOCIATION WITH TAMOXIFEN INDUCED HOTFLASHES IN PAKISTANI FEMALE BREAST CANCER PATIENTS

  2015cites this paper
• Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.

  2015cites this paper
• CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients.

  2015cites this paper
• Pharmacogenetics and Antineoplastic Therapies

  2015cites this paper
• Contribution of ABCB 1 and CYP 2 D 6 Genotypes to the Outcome of Tamoxifen Adjuvant Treatment in Premenopausal Women With Breast Cancer

  2015cites this paper
• The Role of Pharmacogenomics in Individualized Medicine

  2015cites this paper
• Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy

  2015cites this paper
• PREVALENCE OF CYP 2 D 6 * 4 GENOTYPE AND ITS ASSOCIATION WITH TAMOXIFEN INDUCED HOT FLASHES IN PAKISTANI FEMALE BREAST CANCER PATIENTS

  2015cites this paper
• Actionable pharmacogenetic markers for prediction and prognosis in breast cancer

  2015cites this paper
• Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment

  2015cites this paper
• Contribution of ABCB1 and CYP2D6 genotypes to the outcome of tamoxifen adjuvant treatment in premenopausal women with breast cancer.

  2015cites this paper
• Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients

  2015cites this paper
• Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective.

  2015cites this paper
• Induction of UDP-Glucuronosyltransferase 2B15 Gene Expression by the Major Active Metabolites of Tamoxifen, 4-Hydroxytamoxifen and Endoxifen, in Breast Cancer Cells

  2015cites this paper
• Tamoxifen Pharmacokinetics Beyond the Genotyping Era

  2015cites this paper
• Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.

  2015cites this paper
• Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen

  2015cites this paper
• Pharmacogenomics–Pharmacoepigenomics of Breast Cancer Therapy: Clinical Implications

  2014cites this paper
• Bioanalysis and clinical pharmacology of tamoxifen in breast cancer

  2014cites this paper
• Personalized Health Care (PHC) in Cancer

  2014cites this paper
• Sulfotransferase 1A1 (SULT1A1) gene expression is regulated by members of the NFI transcription factors in human breast cancer cells

  2014cites this paper
• Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.

  2014cites this paper
• Determination of CYP2D6 *3, *4, and *10 frequency in women with breast cancer in São Luís, Brazil, and its association with prognostic factors and disease-free survival

  2014cites this paper
• The Effects of a Novel Hormonal Breast Cancer Therapy, Endoxifen, on the Mouse Skeleton

  2014cites this paper
• Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.

  2014cites this paper
• Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity.

  2014cites this paper
• Clinical Implementation of Germ Line Cancer Pharmacogenetic Variants During the Next‐Generation Sequencing Era

  2014cites this paper
• Application of genotype-guided cancer therapy in solid tumors.

  2014cites this paper
• Tamoxifen and Irinotecan Pharmacogenomics

  2014cites this paper
• Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis.

  2014cites this paper
• Pharmacogenetics of SULT1A1.

  2014cites this paper
• Implementation of pharmacogenetics in evidence-based medicine: Toward advancing personalized medicine

  2014cites this paper
• Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.

  2014influential citation
• Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen.

  2014cites this paper
• Pharmacogenomics and Personalized Medicines in Cancer Treatment

  2014cites this paper